ClinicalTrials.gg
CompletedNCT00989989REVEALUpdated Oct 18, 2012Results posted

Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema

A Phase 3 interventional study of Ranibizumab and Laser photocoagulation in Diabetic Macular Edema, sponsored by Novartis. Completed at 35 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-18.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies testing ranibizumab in Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Edema.

Enrollment
2nd of 13
396 · median 50
Started
2009
the only one that year
Phase 3
5 of 13
none open now
Registered
5th of 13
by date
Lead sponsor
2 of 13
Novartis

Among the 13 studies testing ranibizumab in Edema, this one is the 2nd largest by enrollment, is the only one that started in 2009, is one of 5 in phase 3, and was the 5th registered.

Edema

568 studies on the registry are indexed under Edema; 97 are open to participants now.

Browse Edema studies →

Open to participants now

None of the 13 studies testing ranibizumab in Edema is open now. The open studies under Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing ranibizumab in Edema as a file.
02

Study summary

This study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or as monotherapy in Asian patients with visual impairment due to Diabetic Macular Edema (DME).

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • DME
  • Diabetic
  • macula
  • edema
  • ranibizumab
  • REVEAL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Type 1 or Type 2 diabetes mellitus according to American Diabetes Association (ADA) or World Health Organization (WHO) guidelines with not more than 10.0% at screening (Visit 1). Patients should be on diet, exercise, and/or pharmacological treatment for diabetes.
  • Patients with visual impairment due to focal or diffuse Diabetic Macular Edema in at least one eye who are eligible for laser treatment in the opinion of the investigator. If both eyes are eligible, the one with the worse visual acuity, as assessed at Visit 1, will be selected for study treatment unless, based on medical reasons, the investigator deems the other eye the more appropriate candidate for study treatment.
  • The study eye must fulfill the following criteria at Visit 1:

    • Best-Corrected Visual Acuity (BCVA) score between 78 and 39 letters, inclusively, using Early Treatment of Diabetic Retinopathy (ETDRS) chart-like visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/160).
    • Decrease in vision is due to DME and not due to other causes, in the opinion of the investigator.
    • Medication for the management of diabetes must have been stable within 3 months prior to randomization and is expected to remain stable during the course of the study.

Exclusion criteria

Exclusion Criteria:

  • Ocular concomitant conditions/ diseases:

    • Concomitant conditions in the study eye which could, in the opinion of the investigator, prevent the improvement of visual acuity on study treatment.
    • Active intraocular inflammation in either eye.
    • Any active infection in either eye.
    • History of uveitis in either eye.
    • Uncontrolled glaucoma in either eye.
  • Ocular treatments:

    • Panretinal laser photocoagulation in the study eye within 6 months prior to or during the study.
    • Focal/grid laser photocoagulation in the study eye within 3 months prior to study entry.
  • Systemic conditions or treatments:

    • History of stroke
    • Renal failure requiring dialysis or renal transplant or renal insufficiency with creatinine level > 2.0 mg/dL.
    • Untreated diabetes mellitus
    • Blood pressure systolic > 160 mmHg or diastolic > 100 mmHg
  • Compliance/ Administrative:

    • Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
396 participants (actual)

Study arms

  • Experimental
    Adjunctive treatment

    Adjunctive administration of ranibizumab 0.5 mg intravitreal injections and active laser.

    Drug: Ranibizumab · Procedure: Laser photocoagulation

  • Experimental
    Monotherapy treatment

    Monotherapy ranibizumab 0.5 mg intravitreal injections plus sham laser.

    Drug: Ranibizumab · Procedure: Sham laser photocoagulation

  • Active comparator
    Laser control

    Active laser treatment plus sham intravitreal injections.

    Procedure: Laser photocoagulation · Drug: Sham ranibizumab

Interventions

  • Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.

  • ProcedureLaser photocoagulation

    Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.

  • DrugSham ranibizumab

    Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.

  • ProcedureSham laser photocoagulation

    Sham laser treatment administered at day 1.

06

What researchers measure

Primary outcomes

  1. Average Change From Baseline of Best-Corrected Visual Acuity (BCVA) Over 12 Months (From Month 1 to Month 12 Compared to Baseline)

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement.

    Time frame: 12 months

Secondary outcomes

  1. Change From Baseline on Central Retinal Subfield Thickness (CRST) at Month 12

    Central Retinal Subfield Thickness (CRST) was measured using Optical Coherence Tomography (OCT) in micrometers. A negative change from baseline of CRST indicates improvement.

    Time frame: 12 months

  2. Percent of Participants With Anatomical Changes in Intra-retinal Cysts at End of Study Compared to Baseline

    Presence or absence of intra-retinal cysts in any of the 6 sections of the study eye was measured using Optical Coherence Tomography (OCT). A complete resolution or decrease from baseline of intra-retinal cysts indicates improvement.

    Time frame: Up to 12 months

  3. Percent of Participants With Anatomical Changes in Sub-retinal Fluid at End of Study Compared to Baseline

    Presence or absence of sub-retinal fluid in any of the 6 sections of the study eye was measured using Optical Coherence Tomography (OCT). A complete resolution or decrease from baseline of sub-retinal fluid indicates improvement.

    Time frame: Up to 12 months

  4. Percent of Participants With Visual Acuity Above 73 Letters at Month 12

    Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at month 12 indicates a positive outcome.

    Time frame: 12 months

  5. Percent of Participants Who Gained >= 10 Letters at Month 12 Compared to Baseline

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A gain of 10 or more BCVA letters from baseline indicates improvement. A BCVA of 84 letters or more at Month 12 indicates improvement.

    Time frame: 12 months

  6. Percent of Participants Who Lost >= 10 Letters at Month 12 Compared to Baseline

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A loss of 10 or more BCVA letters from baseline indicates worsening.

    Time frame: 12 months

  7. Percent of Participants Who Gained >= 15 Letters at Month 12 Compared to Baseline

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A gain of 15 or more BCVA letters from baseline indicates improvement. A BCVA of 84 letters or more at Month 12 indicates improvement.

    Time frame: 12 months

  8. Percent of Participants Who Lost >= 15 Letters at Month 12 Compared to Baseline

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A loss of 15 or more BCVA letters from baseline indicates worsening.

    Time frame: 12 months

  9. Best-Corrected Visual Acuity (BCVA) Mean Change From Baseline at Month 12

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.

    Time frame: 12 months

  10. Patient Outcome Measure Euro Quality of Life Questionnaire (EQ-5D)

    The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Participants self-rate their health on a visual, vertical analogue scale from 0 to 100 where the endpoints are labeled "Best imaginable health state" (100) and "worst imaginable health state" (0).

    Time frame: 12 months

07

Results

Posted Oct 18, 2012

Participant flow

Participant flow — Overall Study
MilestoneAdjunctive TreatmentMonotherapy TreatmentLaser Control
Started132133131
Completed114123108
Not completed181023

Outcome measures

PrimaryAverage Change From Baseline of Best-Corrected Visual Acuity (BCVA) Over 12 Months (From Month 1 to Month 12 Compared to Baseline)

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement.

Time frame:
12 months
Reported as:
Mean · Letters
Average Change From Baseline of Best-Corrected Visual Acuity (BCVA) Over 12 Months (From Month 1 to Month 12 Compared to Baseline)
LettersAdjunctive TreatmentMonotherapy TreatmentLaser Control
Average Change From Baseline of Best-Corrected Visual Acuity (BCVA) Over 12 Months (From Month 1 to Month 12 Compared to Baseline)5.7 ± 7.205.9 ± 6.021.4 ± 6.49
SecondaryChange From Baseline on Central Retinal Subfield Thickness (CRST) at Month 12

Central Retinal Subfield Thickness (CRST) was measured using Optical Coherence Tomography (OCT) in micrometers. A negative change from baseline of CRST indicates improvement.

Time frame:
12 months
Reported as:
Mean · micrometers
Change From Baseline on Central Retinal Subfield Thickness (CRST) at Month 12
micrometersAdjunctive TreatmentMonotherapy TreatmentLaser Control
Change From Baseline on Central Retinal Subfield Thickness (CRST) at Month 12-171.8 ± 160.85-134.6 ± 131.17-57.2 ± 118.60
SecondaryPercent of Participants With Anatomical Changes in Intra-retinal Cysts at End of Study Compared to Baseline

Presence or absence of intra-retinal cysts in any of the 6 sections of the study eye was measured using Optical Coherence Tomography (OCT). A complete resolution or decrease from baseline of intra-retinal cysts indicates improvement.

Time frame:
Up to 12 months
Reported as:
Number · percentage of participants
Percent of Participants With Anatomical Changes in Intra-retinal Cysts at End of Study Compared to Baseline
percentage of participantsAdjunctive TreatmentMonotherapy TreatmentLaser Control
complete resolution19.521.86.5
decrease40.342.335.1
no change5.25.115.6
increase1.31.310.4
not applicable2.61.30
missing31.228.232.5
SecondaryPercent of Participants With Anatomical Changes in Sub-retinal Fluid at End of Study Compared to Baseline

Presence or absence of sub-retinal fluid in any of the 6 sections of the study eye was measured using Optical Coherence Tomography (OCT). A complete resolution or decrease from baseline of sub-retinal fluid indicates improvement.

Time frame:
Up to 12 months
Reported as:
Number · percentage of participants
Percent of Participants With Anatomical Changes in Sub-retinal Fluid at End of Study Compared to Baseline
percentage of participantsAdjunctive TreatmentMonotherapy TreatmentLaser Control
complete resolution13.633.325.0
decrease18.211.118.8
no change4.506.3
increase000
not applicable31.818.512.5
missing31.837.037.5
SecondaryPercent of Participants With Visual Acuity Above 73 Letters at Month 12

Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at month 12 indicates a positive outcome.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percent of Participants With Visual Acuity Above 73 Letters at Month 12
percentage of participantsAdjunctive TreatmentMonotherapy TreatmentLaser Control
Percent of Participants With Visual Acuity Above 73 Letters at Month 1220.516.58.5
SecondaryPercent of Participants Who Gained >= 10 Letters at Month 12 Compared to Baseline

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A gain of 10 or more BCVA letters from baseline indicates improvement. A BCVA of 84 letters or more at Month 12 indicates improvement.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Percent of Participants Who Gained >= 10 Letters at Month 12 Compared to Baseline
Percentage of participantsAdjunctive TreatmentMonotherapy TreatmentLaser Control
Percent of Participants Who Gained >= 10 Letters at Month 12 Compared to Baseline37.2 ± 37.233.8 ± 33.813.3 ± 13.3
SecondaryPercent of Participants Who Lost >= 10 Letters at Month 12 Compared to Baseline

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A loss of 10 or more BCVA letters from baseline indicates worsening.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Percent of Participants Who Lost >= 10 Letters at Month 12 Compared to Baseline
Percentage of participantsAdjunctive TreatmentMonotherapy TreatmentLaser Control
Percent of Participants Who Lost >= 10 Letters at Month 12 Compared to Baseline5.43.06.3
SecondaryPercent of Participants Who Gained >= 15 Letters at Month 12 Compared to Baseline

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A gain of 15 or more BCVA letters from baseline indicates improvement. A BCVA of 84 letters or more at Month 12 indicates improvement.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Percent of Participants Who Gained >= 15 Letters at Month 12 Compared to Baseline
Percentage of participantsAdjunctive TreatmentMonotherapy TreatmentLaser Control
Percent of Participants Who Gained >= 15 Letters at Month 12 Compared to Baseline17.818.87.8
SecondaryPercent of Participants Who Lost >= 15 Letters at Month 12 Compared to Baseline

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A loss of 15 or more BCVA letters from baseline indicates worsening.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Percent of Participants Who Lost >= 15 Letters at Month 12 Compared to Baseline
Percentage of participantsAdjunctive TreatmentMonotherapy TreatmentLaser Control
Percent of Participants Who Lost >= 15 Letters at Month 12 Compared to Baseline3.91.53.9
SecondaryBest-Corrected Visual Acuity (BCVA) Mean Change From Baseline at Month 12

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.

Time frame:
12 months
Reported as:
Mean · Letters
Best-Corrected Visual Acuity (BCVA) Mean Change From Baseline at Month 12
LettersAdjunctive TreatmentMonotherapy TreatmentLaser Control
Best-Corrected Visual Acuity (BCVA) Mean Change From Baseline at Month 126.4 ± 10.676.6 ± 7.681.8 ± 8.27
SecondaryPatient Outcome Measure Euro Quality of Life Questionnaire (EQ-5D)

The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Participants self-rate their health on a visual, vertical analogue scale from 0 to 100 where the endpoints are labeled "Best imaginable health state" (100) and "worst imaginable health state" (0).

Time frame:
12 months
Reported as:
Mean · units on a scale
Patient Outcome Measure Euro Quality of Life Questionnaire (EQ-5D)
units on a scaleAdjunctive TreatmentMonotherapy TreatmentLaser Control
Patient Outcome Measure Euro Quality of Life Questionnaire (EQ-5D)2.8 ± 14.38-1.1 ± 12.741.0 ± 13.90

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Monotherapy Treatment—21/133 (15.8%)36/133 (27.1%)
Adjunctive Treatment—22/132 (16.7%)36/132 (27.3%)
Laser Control—19/128 (14.8%)23/128 (18%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventMonotherapy TreatmentAdjunctive TreatmentLaser Control
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/1330/1322/128
Cerebral infarctionNervous system disorders0/1330/1322/128
Cardiac failure chronicCardiac disorders0/1332/1320/128
Cataract (Fellow eye)Eye disorders1/1332/1320/128
Cataract (Study eye)Eye disorders0/1332/1320/128
Endophthalmitis (Study eye)Infections and infestations1/1332/1320/128
Angina pectorisCardiac disorders2/1330/1321/128
Maculopathy (Fellow eye)Eye disorders2/1330/1320/128
Vitreous haemorrhage (Fellow eye)Eye disorders2/1330/1321/128
Traumatic intracranial haemorrhageInjury, poisoning and procedural complications2/1330/1320/128
Most frequent other events
Most frequent other events
EventMonotherapy TreatmentAdjunctive TreatmentLaser Control
Conjunctival haemorrhage (Study eye)Eye disorders17/13312/1327/128
Diabetic retinal oedema (Fellow eye)Eye disorders11/1338/1322/128
NasopharyngitisInfections and infestations10/13310/1328/128
HypertensionVascular disorders6/1337/1326/128

Baseline characteristics

Age Continuous
Age Continuous(years)Adjunctive TreatmentMonotherapy TreatmentLaser ControlTotal
Mean61.2 ± 10.5260.7 ± 9.3761.5 ± 9.6861.1 ± 9.85
Sex: Female, Male
Sex: Female, Male(Participants)Adjunctive TreatmentMonotherapy TreatmentLaser ControlTotal
Female655256173
Male678175223
08

Study locations

35 sites
  • Novartis Investigative Site
    Beijing, China
  • Novartis Investigative Site
    Changsha, China
  • Novartis Investigative Site
    Chengdu, China
  • Novartis Investigative Site
    Chongqing, China
  • Novartis Investigative Site
    Guangzhou, China
  • Novartis Investigative Site
    Hangzhou, China
  • Novartis Investigational Site
    Shanghai, China
  • Novartis Investigative Site
    Wenzhou, China
  • Novartis Investigative Site
    Xi'an, China
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Chiba, Japan
  • Novartis Investigative Site
    Chiyoda-ku, Japan
  • Novartis Investigative Site
    Chuo-ku, Japan
  • Novartis Investigative Site
    Fukuoka, Japan
  • Novartis Investigative Site
    Fukushima, Japan
  • Novartis Investigative Site
    Hirakata, Japan
  • Novartis Investigative Site
    Kita-gun, Japan
  • Novartis Investigative Site
    Kobe, Japan
  • Novartis Investigative Site
    Kyoto, Japan
  • Novartis Investigative Site
    Mitaka, Japan
  • Novartis Investigative Site
    Nagoya, Japan
  • Novartis Investigative Site
    Osaka, Japan
  • Novartis Investigative Site
    Otsu, Japan
  • Novartis Investigative Site
    Shimotsuke, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Japan
  • Novartis Investigative Site
    Suita, Japan
  • Novartis Investigative Site
    Toyko, Japan
  • Novartis Investigative Site
    Urayasu, Japan
  • Novartis Investigative Site
    Wakayama, Japan
  • Novartis Investigative Site
    Yamagata, Japan
  • Novartis Investigative Site
    Seoul, Korea, Republic of
  • Novartis Investigative Site
    Singapore, Singapore
  • Novartis Investigative Site
    Kaohsiung, Taiwan
  • Novartis Investigative Site
    LinKou, Taiwan
  • Novartis Investigative Site
    Taipei, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2009
First posted
Oct 6, 2009
Start
Sep 2009
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Oct 18, 2012
Last update
Oct 18, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00989989
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Oct 6, 2009
Start date
Sep 2009
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Oct 18, 2012
Last update
Oct 18, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion